Screening of Metabolism-Disrupting Chemicals on Pancreatic α-Cells Using In Vitro Methods

Reinaldo Sousa Dos Santos1,2, Ignacio Babiloni-Chust1,2, Laura Marroqui1,2

  • 1Instituto de Investigación, Desarrollo e Innovación en Biotecnología Sanitaria de Elche (IDiBE), Universidad Miguel Hernández de Elche, 03202 Elche, Alicante, Spain.

Insights

Metabolism-disrupting chemicals (MDCs) can harm alpha-cells, impacting glucagon secretion and potentially diabetes risk. New methods using mouse alpha-cells can identify MDCs that affect cell viability and function.

Area of Science:

  • Endocrinology
  • Toxicology
  • Cell Biology

Background:

  • Metabolism-disrupting chemicals (MDCs) are endocrine disruptors linked to obesity and diabetes.
  • Limited data exists on MDC effects on pancreatic alpha-cells, crucial for glucose homeostasis.
  • Novel methods are needed to identify MDCs affecting alpha-cell function and viability.

Purpose of the Study:

  • To evaluate the impact of six common MDCs on mouse alpha-cell viability and glucagon secretion.
  • To establish and validate a testing model for identifying diabetogenic MDCs.
  • To investigate the mechanisms underlying MDC-induced alpha-cell dysfunction.

Main Methods:

  • Utilized the mouse alpha-cell line αTC1-9 for in vitro testing.
  • Assessed cell viability using MTT assay and DNA-binding dyes.
  • Measured glucagon secretion and analyzed reactive oxygen species (ROS) and endoplasmic reticulum (ER) stress markers.

Main Results:

  • Bisphenol-A (BPA) and tributyltin (TBT) reduced alpha-cell viability through estrogen receptor and PPARγ activation, respectively, inducing ROS.
  • Perfluorooctanoic acid (PFOA), triphenylphosphate (TPP), triclosan (TCS), and dichlorodiphenyldichloroethylene (DDE) did not affect cell viability but impaired glucagon secretion.
  • ER stress markers were minimally altered by the tested MDCs.

Conclusions:

  • The αTC1-9 cell line is a suitable model for assessing MDC metabolism-disrupting activity.
  • Proposed testing methods can be integrated into screening protocols for diabetogenic MDCs.
  • MDCs differentially impact alpha-cell viability and function, highlighting the need for targeted risk assessment.

Related Concept Videos